Skip to main content

NEWS BRIEF: Exelixis, Merck to Build Small-Molecule Libraries

NEW YORK, May 1 - Exelixis and pharma giant Merck will design and develop small-molecule compound libraries for high-throughput drug screening, Exelixis said today.


Both firms will own the libraries, which will be used for internal lead-discovery programs as well as in collaborative research ventures, the partners said.

Exelixis will bring to the table small molecules, analytics, informatics, and formatting.


Click here for more information.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.